Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization -215% Improvement Relative Risk Symptomatic case -40% Case -5% c19hcq.com Oztas et al. HCQ for COVID-19 PrEP Favors HCQ Favors control
Oztas, 650 patient HCQ prophylaxis study: 215% higher hospitalization [p=0.36], 40% more symptomatic cases [p=0.44], and 5% more cases [p=0.88] https://c19p.org/oztas
copied to clipboard
Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine
Oztas et al., Journal of Medical Virology, doi:10.1002/jmv.27731
21 Mar 2022    Source   PDF   Share   Tweet
Retrospective 317 HCQ users and 333 household contacts, showing higher risk with HCQ.
Authors do not adjust for the very different baseline risk for systemic autoimmune disease patients. Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [Ferri].
risk of hospitalization, 215.1% higher, RR 3.15, p = 0.36, treatment 3 of 317 (0.9%), control 1 of 333 (0.3%).
risk of symptomatic case, 40.1% higher, RR 1.40, p = 0.44, treatment 16 of 317 (5.0%), control 12 of 333 (3.6%).
risk of case, 5.0% higher, RR 1.05, p = 0.88, treatment 22 of 317 (6.9%), control 22 of 333 (6.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: not adjusting for the different baseline risk of systemic autoimmune patients, excessive unadjusted differences between groups.
Oztas et al., 21 Mar 2022, retrospective, Turkey, peer-reviewed, 15 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit